Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIMPLIFY: Sofosbuvir/Velpatasvir for HCV in People Who Inject Drugs
NCT02336139Phase 2Completed
- Sponsor
- The Kirby Institute
- Start
- Mar 2016
- Primary completion
- Apr 2017
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sofosbuvir and velpatasvir in hepatitis C (HCV), sponsored by The Kirby Institute. Primary endpoint: Sustained Virological Response at 12 weeks post-treatment. Started Mar 2016; status: completed.
02
Drugs
sofosbuvirvelpatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02336139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02336139.